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Abstract: Many inflammatory diseases have an oxidative aetiology, which leads to oxidative 
damage to biomolecules, including proteins. It is now increasingly recognized that oxidative 
post-translational modifications (oxPTMs) of proteins affect cell signalling and behaviour, 
and can contribute to pathology. Moreover, oxidized proteins have potential as biomarkers 
for inflammatory diseases. Although many assays for generic protein oxidation and breakdown 
products of protein oxidation are available, only advanced tandem mass spectrometry approaches 
have the power to localize specific oxPTMs in identified proteins. While much work has 
been carried out using untargeted or discovery mass spectrometry approaches, identification 
of oxPTMs in disease has benefitted from the development of sophisticated targeted or 
semi-targeted scanning routines, combined with chemical labeling and enrichment approaches. 
Nevertheless, many potential pitfalls exist which can result in incorrect identifications. 
This review explains the limitations, advantages and challenges of all of these approaches 
to detecting oxidatively modified proteins, and provides an update on recent literature in 
which they have been used to detect and quantify protein oxidation in disease. 
Keywords: oxidative post-translational modification; inflammation; cardiovascular disease; 
protein carbonyls; nitrotyrosine; chlorotyrosine; LC-MS/MS; precursor ion scanning; neutral 
loss scanning; multiple reaction monitoring 
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1. Introduction to Protein Oxidation 
Many diseases have an oxidative aetiology resulting from activation of the immune system, 
mitochondrial dysfunction or environmentally-induced oxidative stress. Oxidative modification of 
proteins can have multiple effects, such as loss of enzymatic activity, functional alterations, loss of 
structural integrity, and protein aggregation [1]. Various different reactive and oxidizing species exist 
and vary in their reactivity to protein residues and sites. Metal-catalysed oxidation depends on the 
formation of hydroxyl radicals through Fenton chemistry; hydroxyl radicals are highly reactive and  
able to modify almost any site through hydrogen abstraction and peroxide formation, often leading to 
backbone fragmentation. The most susceptible side chains in proteins are the sulfur-containing cysteine 
and methionine side chains; the reactivity of cysteine with hydrogen peroxide depends on the pKa of 
the thiol group as the thiolate anion is a better nucleophile. Cysteine can also react with reactive nitrogen 
species to form nitrosothiols (Figure 1). Other residues that are commonly oxidized include histidine, 
proline, lysine and arginine, where hydroxylation or formation of aldehydes or ketones may occur. 
Reactive nitrogen compounds derived from peroxynitrite are often both nitrating and oxidizing. Sites 
susceptible to nitration include tyrosine (forming 3-nitrotyrosine) and tryptophan. Hypohalites can also 
react with aromatic residues to form halogenated products such as 3-chloro and 3-bromotyrosine [2]. 
 
Figure 1. Structures of oxidized residues most commonly detected and studied by mass 
spectrometry. In mixed disulfides, R can be cysteine or glutathione (glutathionylation).
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Protein oxidation is often measured as a marker of oxidative damage and cellular stress, and a wide 
variety of methods exist, varying from simple global methods to specific approaches to detecting individual 
modified residues [3]. A commonly measured modification is carbonyl formation, which can occur on 
lysine, arginine, serine, threonine and proline residues following metal-catalysed oxidation or attack  
by hypochlorous acid. Carbonyl groups react with DNPH (2,4-dinitrophenylhydrazine) and other 
aldehyde reaction probes such as N'-amino-oxymethylcarbonylhydrazino-D-biotin, offering potential for 
colorimetric detection or selective enrichment approaches. Anti-DNP antibodies form the basis of 
carbonyl-focused western blotting (“oxy-blotting”) and ELISAs [3,4]. Total digestion followed by 
HPLC, LC-MS or LC-MS/MS has been used to investigate a wide range of oxidized amino acids [5], 
but these approaches do not provide information on the specific protein that has been modified, or the 
exact site of modification. 
Mass spectrometry has been used for many years for identification and characterization of proteins, 
and is arguably the most informative method for determining oxidative modification of proteins 
currently available. This article gives an overview of advances and limitations of LC-MS/MS approaches 
for detecting specific non-enzymatic oxidative modifications to proteins, and summarizes their recent 
application in studies of disease. 
2. Overview of Mass Spectrometry Methods for Protein Oxidation Analysis 
Mass spectrometry measures the mass-to-charge ratio (m/z) of ionized analytes, and as oxidative 
modifications alter the chemical composition of a protein, they change the m/z ratio of the intact 
protein and of the residues where the oxidation occurred; thus, MS is a powerful method for detecting 
oxidative post-translational modifications (oxPTMs) [2]. Mass spectrometry approaches for the analysis of 
proteins, both native or oxidized, have advanced substantially in recent years, and can essentially be 
divided into “top-down”, which involves analysis of intact proteins and their fragmentation within  
the mass spectrometer, and “bottom-up” analysis, in which proteins are enzymatically digested to  
a peptide mixture before being introduced to the instrument (Figure 2). The latter is by far the more 
common method, as it is extensively used in proteomics studies to sequence and identify proteins in 
biological samples, and has been extended to investigate protein oxidation. However, while identification 
of proteins using search engines to match experimental MS data against protein sequence databases  
is now routine, the analysis of post-translational modification, including oxidative modifications, 
continues to be extremely challenging. Consequently, there is a continual search for methodologies 
that facilitate identification of oxPTMs. This has led to the development of targeted mass spectrometry 
routines that search for peptides containing ions that are diagnostic for the presence of an oxidative 
modification, such as chlorotyrosine or methionine sulfoxide. Alternatively, the use of chemical 
reagents that react with oxidative modifications, which can be used as tags to label modified peptides 
or proteins, can facilitate both enrichment and detection and has seen significant recent development; 
carbonyl-reactive probes are a major focus of this approach. For all of these methods, an overarching 
aim is to be able to quantify the level of oxPTM, either in absolute terms or relative to the level of total 
protein. Advances in these different strategies are described in more detail in the following sections. 
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Figure 2. Summary of advanced methods for identification of proteins and oxPTMs. Labeling 
and enrichment can also be carried out at the protein level, but this approach is less common. 
2.1. Sample Preparation and Digestion 
An important practical consideration for any study of protein oxidation is how to minimize oxidative 
artefacts caused by sample processing. Bottom-up strategies usually involve digestion in solution or 
one or two-dimensional gel electrophoresis followed by in-gel digestion; both methods have been 
shown to introduce artefacts such as methionine, cysteine or tryptophan oxidation [6], so care is needed 
to minimise exposure to air and in the interpretation of results. Adventitious oxidation, such as artefactual 
S-thiolation of reactive, surface-exposed cysteine residues, has also been identified as a problem in  
top-down MS [7]. 
Protein digestion strategies for bottom-up approaches depend to a great extent on the type of 
experiment, but there are important considerations for mapping oxPTMs. Where comprehensive mapping 
of oxidative modifications of proteins is the aim and as close to complete sequence coverage as possible 
is required, or for studying modifications of specific residues within a protein where trypsin does not yield 
an appropriate peptide for MS, it is often necessary to use alternative proteases to the commonly used 
trypsin that cleave at different residues, or even combinations of proteases. Many alternative proteases 
with orthogonal activities to trypsin have been used successfully in recent years, including chymotrypsin 
(large hydrophobic), Asp-N (N-terminal to asp), Glu-C (N-terminal to Asp and Glu) and others [8–10]. 
Selective proteolytic cleavage may also be used to help to identify oxidative modifications; for example, 
AspN or GluC also cleave at cysteine sulfonic acid and trypsin at aminoethylcysteine [11], and pepsin 
can be used at low pH, which minimizes disulphide interchange [12]. New digestion methods that may 
help to minimize sample handling, and thus adventitious oxidation, include in-line digestion where  
the sample is passed through a column of beads coated with trypsin, which digests the proteins as  
they flow through [13,14]. MS friendly surfactant additives, such as ProteaseMax (Promega) [15,16] and 
Rapigest (Waters) [17], and on-membrane [18] or in-pellet digestion [15] have all been shown to 
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improve sample digestion efficiency and recovery of peptides, and thus give increased sequence coverage 
and may improve coverage of modifications; in one study, 1000 S-glutathionylated sites on proteins 
were identified using in-pellet digestion [19]. 
2.2. Enrichment and Separation 
In addition to limiting adventitious oxidation as mentioned in the previous section, it can also be 
useful to stabilize labile oxidative modifications that are genuinely sample-derived. Moreover, chemical 
labeling of modifications offers the possibility of enrichment by tag-specific binding systems, thus reducing 
the complexity of samples and facilitating detection of the oxPTM of interest. Affinity enrichment 
methods are useful for oxPTMs directly, using antibodies to the modification or chemical tag, or other 
resin-based capture agents, or based on chemical reactivity (for example thiopropyl sepharose [20]). 
However, significant care and accurate quantification, as well as appropriate experimental protocols, 
are necessary to minimise non-specific interactions with the solid support and identify these in the 
subsequent data analysis [21,22]. Immunoenrichment with antibodies against oxPTMs (for example 
anti-nitrotyrosine antibodies) has been used to enrich proteins from biological samples [23], although 
this is not always successful [24] and can introduce a high background of immunoglobulins and other 
proteins into the sample. In addition, the lack of specificity in immunoenrichment exhibited by many 
antibodies can significantly compromise this approach. 
Overall there are many different chemical labeling and enrichment strategies for detecting and 
quantifying oxidations. The biotin-switch method has been developed to detect reversible cysteine 
oxidations such as disulfides, sulfenic acids (-SOH) and S-nitrosothiols (-SNOs) [25]. The principle is 
that free thiols are first blocked with an alkylating agent (e.g., iodoacetamide), then the oxidative 
modifications are selectively reduced; for example, using DTT for disulfides, ascorbate for SNOs or 
arsenite for sulfenic acids, followed by biotinylation with a thiol-reactive biotin reagent. This allows 
enrichment by avidin affinity capture [26]. Careful consideration also needs to be given to the protocols 
for these approaches to ensure residual reducing, oxidising or alkylating agents are properly quenched, 
or that a significant excess of reagent is used, at each step. The limitations of this approach are the low 
throughput and difficulty in localising the modification by MS, as ionisation efficiency and peptide 
fragmentation are often compromised by biotinylation. Recently, some of these issues have been resolved 
and a quantitative method developed using commercially available iodoacetyl tandem mass tag 
(iodoTMT) reagents, as described in Section 6 [27]. An alternative method developed for the enrichment 
of SNOs is the use of organic mercury columns, which involves covalent bond formation between  
the SNO and mercury. The modified proteins can be digested while bound on the column before elution 
and MS analysis [28]. Protein carbonyl groups are reactive and can also be labelled by nucleophilic 
reagents and linked to biotin for enrichment [29]. DNPH is a well-established carbonyl-label and has 
the advantage that it can act as the matrix for matrix-assisted laser desorption/ionisation (MALDI-) MS, 
which provides increased specificity and sensitivity for carbonyl-containing peptides and eliminates the 
need for upstream enrichment. DNPH-labelled peptides can also be analysed with data-dependent 
acquisition methods with ESI-MS [30]. This technique has recently been applied to a proteome-wide 
study of protein carbonyl groups generated by mild oxidation; 210 carbonylated proteins were identified 
with a total of 643 carbonyl locations detected in the HeLa cell proteome [31]. 
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Chemical tagging approaches have also been used to detect the formation of protein bound 
nitrotyrosine; the initial step is reduction of the nitro group to an amine, which is more amenable  
to tagging. A wide variety of reduction, labeling and enrichment methods, for example using  
N-succinimidyl-S-acetylthioacetate [32] or dansyl chloride [33], have been reported, and reviewed 
recently [34]. Usually this approach is reported to give an improvement in selectivity, and indeed 
enrichment steps have often been regarded as essential. Several of the tags can also be used as 
reporters in subsequent MS analysis [33]. 
Developments in LC-separation are also desirable in order to reduce sample loading and improve 
separation of proteins and peptides. Gel eluted liquid fraction entrapment electrophoresis (GELFrEE) 
integrates gel electrophoresis separation within reverse phase LC, and eliminates the need for prior 
electrophoresis and sample processing before injection into the LC [35]. It has been applied to the 
detection of nitrotyrosine using the increased hydrophilicity of aminotyrosine (formed by reduction of 
nitrotyrosine with dithionite) and concomitant shift in chromatographic elution of modified peptides  
on reverse phase HPLC [36]. In contrast, for top-down studies the favoured method is Capillary Zonal 
Electrophoresis (CZE), which allows lower sample loading and has higher separation efficiency than 
reverse phase HPLC [37,38]. This can facilitate detection of oxidation in complex clinical samples, 
where protein concentration may be limited. 
2.3. Intact Protein and Top-Down Analysis 
Intact protein analysis, where MS is used to determine the mass of the intact protein and changes  
in mass can be indicative of modifications to the protein structure, is a well-established approach.  
Both MALDI and ESI have been used, although ESI is the more common method as it is generally 
able to give mass accuracies better than 1 in 10,000 on most instruments. This accuracy is due to the 
protein acquiring more than one charge during ionization, usually many different charges, giving rise to a 
number of peaks in the spectrum (since MS measures mass-to-charge ratio, each different charge state 
will give rise to a separate peak in the spectrum) [39]. This set of peaks can be used to help reduce 
errors in the calculation of the mass, and this has been enhanced further by the ability of high 
resolution instruments to separate the individual isotopic peaks for even very large proteins, enabling 
the analysis of larger proteins including antibodies [40] and even protein complexes [41]. However, 
this multiple charging means that only a limited number of proteins or different protein species can  
be present in the sample before signals start to overlap and deconvolution becomes more difficult.  
This method can provide useful information on the total load of modifications on an individual protein 
molecule [42], and has been applied successfully to detecting methionine oxidation [43], glutathionylated 
haemoglobin [44] and electrophilic modifications [45], although for small modifications, high-resolution 
instruments such as Q-TOFs, Orbitraps or FT-ICR MS are really needed for accurate determination of 
multiple different forms. However, in order to determine the site of modification, either bottom-up or 
top-down methods are needed. Top-down MS is an emerging platform that involves fragmentation of 
the intact protein within the mass spectrometer, and analysis of the large fragments produced.  
It requires high-resolution mass spectrometers and alternative fragmentation technologies that are not 
available on all instruments. It is currently limited in sensitivity and struggles to deal with complex 
samples, but has great potential for mapping protein oxidation [46–48]. Most top-down studies have 
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been conducted in vitro with low molecular weight proteins, although more recently a range of 30–80 kDa 
proteins in a whole cell lysate of P. aeruginosa have been analysed [38]. The top-down approach  
has the advantage of providing additional information on the relative occupancy of oxidation and 
relationships of oxidised residues to one another in the whole protein [46,49,50]. For example, methionine 
oxidation and nitrotyrosine have been detected and quantified in calmodulin following incubation with 
lipopolysaccharide (LPS)-activated macrophage lysate [50]. The oxidation of multiple methionine 
residues has also been quantified using top-down approaches in filgrastim, a granulocyte colony-stimulating 
factor, to determine the effects of methionine oxidation on biopharmaceutical shelf life [49]. However, 
despite these reports, the methodology is still some way short of being applied to the detection of 
protein oxidation in disease. 
2.4. Bottom-Up Analysis 
Bottom-up proteomics differs from top-down analysis in that the proteins are digested to peptides  
as mentioned in Section 2.1. Specific labeling and enrichment strategies can be implemented at this 
stage, as described in the previous section, although label-free methods are more common in standard 
proteomics. In all bottom-up methods, quantification is restricted to the peptide level, and cannot be 
used to infer relationships between oxidations on different peptides within an individual protein. 
Bottom-up protein analysis is most commonly conducted by LC-MS/MS using either untargeted 
analysis (often referred to as a shotgun or discovery approach, and described further in Section 3), or 
semi-targeted/targeted approaches [51], which are described in Section 4. The former is most common, 
but the limitations of this approach for detecting oxidative modifications lie in the automated selection 
of the peptides to be fragmented, which tends to be those that give strongest signals in the preliminary 
MS scan, whereas oxidized peptides are typically present at very low abundance [52]. Hence there  
has been significant effort recently in developing targeted and semi-targeted methods that depend on 
scanning for reporter ions in the MS or MS/MS spectra that are diagnostic for the presence of an 
oxidative modification. This requires some prior knowledge, at least of the fragmentation characteristics 
of the oxidative modification, and for some methods additionally the specific peptide modified. 
These mass spectrometry-based methods can be implemented either in label-free or label-dependent 
strategies. Label-free approaches are widely used in standard proteomic analysis, and even for analysis 
of oxidatively modified proteins they have the advantage of less sample manipulation. With regard to 
identification of oxidative modifications, label-dependent methods usually refer to modification-specific 
chemical tagging, in contrast to the isotope-labeling techniques used for more generic quantification, although 
a few studies have combined these methods for quantifying modifications (Section 5). Label-dependent 
MS approaches often take advantage of reporter ions from the label to indicate the presence of a 
modification in a peptide, which can then be targeted for further analysis, and are discussed further  
in Section 4. 
3. Untargeted Mass Spectrometry and “Discovery” Approaches 
A large proportion of proteomics and MS methods are focused on identification and quantification 
of specific proteins in diverse samples, in order to understand proteomic changes in disease or other 
conditions. Analysis of oxidative modifications in proteins represents a much smaller field, and although 
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specific methodologies are being developed and utilized, much research is still carried out using 
untargeted approaches (Figure 2). 
3.1. Use of Search Engines for MS Data and Analysis of oxPTMs 
LC-MS/MS experiments generate very large datasets that are difficult to manually analyse, and 
consequently many statistical search engines have been recently introduced or further developed for 
identification of proteins from MS/MS data; some of the most commonly used examples are Mascot, 
PEAKS, Sequest, ProteinPilot, Tandem, Ommsa and Phenyx [53–56] (Table 1). While generally these 
programmes work very well for identifying proteins, more issues arise when trying to identify 
oxPTMs, at least using standard parameter settings [57], and some of the advantages and disadvantages 
that have been observed are identified in Table 1. 
Table 1. Comparison of the advantages and disadvantages of the most commonly used 
search engines for peptide and protein identification. 
Search 
Engine 
Method Advantages Disadvantages 
Mascot 
Uses a probability modelling algorithm 
and protein database searching. Matches 
experimental peptide and fragment ion 
masses to ones generated in silico from 
databases. 
User-friendly interface. Provides 
an error-tolerant search facility. 
Sophisticated but complex data 
export possibilities. 
Very reliant on user input for 
correct identification of oxPTMs, 
otherwise false positives and 
negatives occur. 
Sequest 
Uses an algorithm based on a cross 
correlation function, plus protein data base 
searching. Matches experimental peptide 
and fragment ion masses to ones generated 
in silico from databases. 
User-friendly interface. Provides 
an error-tolerant search facility. 
Very reliant on user input for 
correct identification of oxPTMs, 
otherwise false positives and 
negatives occur. 
ProteinPilot 
Uses a sequence tag method plus protein 
database searching. 
User-friendly interface. Potentially 
better at identifying unsuspected 
modifications. 
If the initial sequence tag is 
incorrectly identified, the experimental 
peptide will not be matched to 
the correct peptide. Long analysis 
run times. 
pMatch 
Spectral library searching against 
experimentally-derived data. 
Has been reported to be better 
at identifying PTMs, and specifically 
at coping with the unusual 
fragmentation of peptides caused 
by PTMs. 
Since this method uses a spectral 
library, the peptide will only be 
identified if the spectra are 
available in the spectral library. 
MS 
Amanda 
Based on a binomial distribution function. 
Protein data base searching. Matches 
experimental peptide and fragment ion 
masses to ones generated in silico from 
databases. 
Reported to be better at identifying 
peptides of higher m/z than Mascot 
and Sequest. 
Very reliant on user input for 
correct identification of oxPTMs, 
otherwise false positives and 
negatives occur. 
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Many search engines offer the possibility of including a wide variety of oxPTMs as variable 
modifications [58], but the number of modifications that can be searched in parallel is usually limited 
to 3–4 to minimize false positive identifications [59], which can be limiting when heterogeneous 
oxidation has occurred. oxPTMs also add additional complications to searching data. For example, the 
spectrum of a peptide containing methionine sulfoxide will include a neutral loss of 64 Da (-CH3SOH), 
which complicates interpretation of the spectrum and sequencing, although this can be improved using 
alternative fragmentation methods [60]. Protein Pilot works in a different way to Mascot, Sequest and MS 
Amanda [61], and is less affected by these constraints, so may have advantages for the analysis of 
complex oxPTMs. It is based on the Paragon algorithm and uses small sequence tags generated by  
de novo sequence analysis of parts of the experimental data. The sequence tag is searched against  
a protein database and any sequence in the database that matches the sequence tag is investigated for  
a fit to the experimental data set, in an iterative approach. All possible PTMs are allowed for in the  
error-tolerant mode. This has the advantage of being a non-statistical method in which a sequence can 
be constructed with the inclusion of a wide variety of oxPTMs, but if the initial sequence tag was 
incorrectly identified, the final peptide will also be incorrect, and the large search space results in  
a time-consuming process. Mascot also incorporates an error-tolerant search function that has been 
substantially developed in recent releases, and does not require a list of anticipated modifications;  
in this mode all possible PTMs are tested against the theoretical peptide and fragment ion masses, and 
the PMT that gives the best match to the experimental data is reported as a match. Again, this increases 
the search time and tends also to increase the false positive rate. 
A new search engine, MS Amanda, has been specifically designed for high resolution instruments; 
it has a different scoring function for identification of the peptides and has been reported to identify 
many more peptides than both Mascot and Sequest, including ones with multiple modifications [62]. 
The resulting increase in sequence coverage could help in identification of oxPTMs, although the 
algorithm is still limited by the same issues. An entirely different approach to identifying peptides  
that is gaining popularity and may help to overcome the limitations of searching for oxPTMs involves 
spectral library searching using a search tool such as pMatch [63]. This method compares the 
experimental MS data with previously acquired spectra in a spectral library using an open search.  
This allows the search engine to search for unknown and unspecified modifications, but depends on 
them being present and correctly identified in the library. 
While statistical software is often used to detect oxidative modifications, comparisons of the results 
from different search engines are rarely performed. Dorfer et al. compared the ability of several search 
engines to identify proteins and post translation modifications [62], while Moskovitz used three search 
engines to detect and localize methionine oxidations [64]. In both instances validation by manual  
de novo sequencing was not performed; this makes it difficult to determine which search engine is the 
most reliable for determining the presence and localisation of oxidative modifications. 
3.2. The Importance of Data Validation 
In view of the potential pitfalls described above, it is essential to validate the MS/MS data by  
de novo sequencing to demonstrate both the presence and location of the modification in the sequence 
(Figure 3), despite it being time-consuming. This process has been reviewed previously [65] and 
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guides to support different levels of expertise are available, e.g., [66]. The software packages to facilitate 
de novo sequencing are continually being developed, such as computer aided manual validation 
software (CAMV), which is compatible with iTRAQ-labeling quantification experiments and has been 
reported to remove approximately 10% of false positives [67]. Other software packages that aid in 
manual validation include PepNovo+, PEAKS, pNovo, MS-GFDB. UniNovo is reported to be best for 
manual validation of Orbitrap MS data [68]. Open source software to improve the user interface of 
packages such as PepNovo+ is also available [69]. A new approach to de novo sequencing by combining 
data from bottom-up and top-down MS approaches has recently been reported to achieve high sequence 
coverage and accuracy [70]. These tools are important, as more widespread use of de novo sequencing  
to validate oxPTMs is needed to ensure that correct relationships between oxPTMs and disease are 
being deciphered. 
 
Figure 3. Incorrectly assigned oxidation to proline using a probability-based search engine. 
(a) Search engine identified 2 modifications on one peptide: methionine-7 mono-oxidation 
and proline-9 oxidation; (b) de novo sequencing showed that methionine is dioxidised.
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4. Reporter Ion-Based Methodologies 
The term reporter ion refers to the formation of ions that are diagnostic for the specific analyte or 
type of analyte of interest, usually product ions from the fragmentation of the peptide. Reporter ions 
have been used in label-free analysis where a sufficiently unique fragment of an oxidized residue has 
been identified; alternatively, several oxidation-specific chemical probes that are MS compatible and 
give diagnostic fragmentations have also been developed. In semi-targeted methods, the fragmentation 
products are diagnostic but the precursors are unknown (Sections 4.1 and 4.2), whereas in fully 
targeted routines both the precursor ion and fragment ions are used as reporters (Section 4.3). In all of 
these approaches, specificity for oxPTMs is improved compared to untargeted analysis and relative 
quantification can be achieved using the relevant precursor ions for oxidized and native peptides. 
4.1. Semi-Targeted MS/MS Analysis 
Neutral loss scanning (NL) and precursor ion scanning (PIS) are two MS/MS routines that enable 
classes of molecular ions to be identified based on a structural feature with a characteristic fragmentation 
pattern. In precursor ion scanning the second analyser is fixed to detect a specific fragment ion  
and scans for precursor ions that generate this product ion upon fragmentation. For analysis of oxidized 
peptides, immonium ions from oxidized residues have been the most commonly reported reporter.  
For example, there have been several reports of the use of the nitrotyosine immonium ion at m/z 181.1 [71], 
and chlorotyrosine (m/z 170.1), hydroxytyrosine (m/z 152.1 Da), and hydroxytryptophan (m/z 175.1 Da) 
have also been tested [42]. However, for each of these isobaric ions from fragmentation of non-modified 
peptides, false positives have been reported; this is particularly a problem on low-resolution instruments 
where the interfering ions are not resolved from the target fragment ion [52,59,72]. One approach 
developed to overcome this problem is a further fragmentation step to yield a more unique combination 
of MS/MS and MS3 (MS/MS/MS, a further fragmentation of a selected ion generated in the MS/MS 
analysis) diagnostic ions; this has been reported for chlorotyrosine, nitrotyrosine, hydroxytyrosine and 
hydroxytryptophan in model proteins and cell lysates using an indirect scanning routine [42,73]. 
Greater specificity can also be obtained using higher-resolution instruments, as has been reported  
for nitrotyrosine [73,74]. 
In neutral loss scanning, the diagnostic fragment is uncharged and is monitored by scanning in  
both analysers with a mass offset corresponding to the mass of the fragment. This methodology has 
been used to identify the presence of oxidized methionine, which has a characteristic neutral loss of 64 Da 
(corresponding to methanesulfenic acid, CH3SOH) [75], and has been applied to measure in oxidation 
of calmodulin [76]. Oxidized cysteine residues fragment in a similar way with different neutral losses 
depending on the extent of modification, as reviewed recently [2]. Schiff base and Michael adducts of 
4-hydroxynonenal with nucleophilic residues can also be monitored by neutral losses of 138 Da and 
156 Da respectively, and has been demonstrated in plasma proteins [77]. 
In addition to these label-free semi-targeted methods, label-dependent approaches have been 
reported. For example, carbonyl-containing proteins or peptides can be labeled with DNPH to form 
hydrazone adducts, which can be analysed in negative ion mode based on a precursor-like scan for 
diagnostic fragments at m/z 152.0, 163.1 and 179.0 [30]. One of the advantages of this technique is  
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the elimination of the need for upstream enrichment during sample preparation, as demonstrated in its 
application to analysis of oxidized proteins in bovine serum albumin and extracts of HeLa cells [30]. 
4.2. Narrow-Window Extracted Ion Chromatograms 
An alternative strategy that has been developed recently as a result of the increasing availability of 
high-resolution mass spectrometers involves generating extracted ion chromatograms (XICs) of 
accurate mass reporter ions from MS/MS data [73]. One study used this technique to quantify the 
levels of S-glutathionylation in haemoglobin F subunits, as evidence of oxidative stress in premature 
infants [44]. However, this strategy has limitations in complex samples where the likelihood of 
isobaric peptides is higher. Alternatively, XICs of diagnostic product ions can be used to mine data for 
oxidative modifications. Recently, this approach was utilized for reporter fragments of nitrotyrosine, 
chlorotyrosine, allysine and for adducts of oxidised phospholipids with proteins [73]. The use of a very 
narrow mass window (0.05 Da) extracted ion chromatogram allowed exclusion of many false positive 
signals from isobaric ions. An advantage of this method is that existing data can be mined retrospectively 
for other modifications, as long as a unique reporter ion can be identified, but a disadvantage is that  
it involves significant manual processing [59,73]. 
4.3. Targeted Methods of Analysis 
Fully-targeted MS/MS approaches involve two related techniques: single reaction monitoring 
(SRM) and multiple reaction monitoring (MRM), where both the precursor ion and product ion masses 
are fixed for the analyte of interest [78]. OxMRM, which combines MRM with protein purification and 
labeling of oxidised cysteine residues with isotope labeled N-ethylmaleimide, has been reported to 
improve sensitivity [79]. Although these targeted approaches are not a discovery strategy as prior 
knowledge of analytes is required, they represent the most accurate available MS-based quantification 
tool and can be conveniently used in hypothesis-driven studies upon optimization of chromatographic 
and mass spectrometric features; further developments of the rapidly developing PeptideAtlas to include 
modifications may greatly extend their utility [80]. 
5. Quantification of (ox)PTMs 
In order to obtain meaningful data on protein oxidation in biological or clinical samples, it is crucial 
to be able to obtain accurate quantitative information about the oxPTMs and their relative abundance 
both within and between samples. Quantitative proteomics strategies can be generally divided into  
label-free and label-based approaches. Label-free techniques rely on comparisons of the abundance of 
the analyte ion intensities directly, with appropriate normalization, whereas label-based approaches 
rely on metabolic or chemical labelling of samples with differentially stable isotope labelled reagents 
and comparison of the ion intensities from these. 
5.1. Label-Free Methods of Quantification 
Label-free methods are becoming the most popular for relative quantification, as they are relatively 
easy to implement and a number of free, open source software packages are available for analysis. 
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However, label-free strategies also need to be used with care when analysing oxPTMs, as these 
modifications will affect both peptide ionisation efficiency and MS/MS fragmentation pattern, complicating 
any comparative analysis. Hence, great care needs to be taken in comparing ion intensities between  
any given peptide and its modified form, especially when the modification removes (e.g., lysine to  
-aminoadipic semialdehyde) or introduces (e.g., cysteine to cysteine sulfonic acid) ionizable groups,  
or alters polar residue composition; using this approach to determine a percentage modification can 
only be semi-quantitative at best, as changes can be very marked. For example, we recently reported  
a 2.6 fold increase in relative signal intensity on nitration of a peptide [81]. Using the loss of the native 
peptide ion intensity could be an alternative, but only where there is significant modification,  
as quantification accuracy is rarely better than 10%. The use of tags that improve ionization, for example 
the iTRAQ (isobaric tags for relative and absolute quantification) label discussed below, may help to 
improve this, although relative quantification of the same modified peptide between samples generated 
under different conditions, or using absolute quantification with a labeled peptide such as in the 
“protein-AQUA” strategy [82] also discussed below, are the only reliable methods. 
The two fundamental strategies currently used in label free quantification are spectral counting and 
feature-based quantification. The different methods have been reviewed elsewhere [83]. Methods based 
on spectral counting rely on the number of identified MS/MS spectra corresponding to a given protein 
as a measure of protein relative abundance. While spectral counting has been used effectively in 
investigations of protein expression changes, including those induced by oxidative stress [84,85], it is 
focused on protein-level quantification and is not well suited for the specific analysis of oxPTMs  
(or many other PTMs) due to their often relatively low stoichiometry and abundance. Feature-based 
quantification methods rely on the comparison of summed peak intensities for each peptide in each  
LC-MS run, following software alignment the different LC-MS runs so that the same features are aligned 
in each data set. With the increasing interest in label-free methods, a new generation of software solutions 
capable of processing large amount of high resolution data have recently become available, including 
Progenesis QI (Non Linear Dynamics, Newcastle upon Tyne, UK), msInspect/AMT [86], MAxQuant [87], 
Rosetta Elucidator (Rosetta Biosoftware, Seattle, WA, USA), OpenMS [88] and Superhirn [89]. Although 
the use of label-free analysis for biomarker discovery in biological samples has been reported [90],  
few studies have reported the use of label-free software based methods for the quantitative 
determination of specific oxPTMs. As for spectral counting, a limitation has been that the methods are 
generally focused on protein-level quantification, and the identification and quantification of individual 
PTMs has been challenging; however, this is improving, and the latest versions of many of the 
programmes now incorporate specific methods for highlighting PTMs. In one recent study, reversibly 
oxidized cysteines in the membrane proteins of human erythrocytes have been quantified using a robust 
computational software-based approach and validated by matching the modified peptides against 
Protein Data Bank entries [91]. 
5.2. Label-Dependent Methods of Quantification 
Label-dependent methods rely on the incorporation of isotope labels into the peptides prior to mass 
spectrometry analysis. Isotope labels can be introduced at various stages of the experimental workflow, 
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depending on type of sample and MS approach. The following section will concentrate on methods 
specific for oxPTMs. 
The use of chemical or enzymatic methods to incorporate the isotopic label after protein digestion 
has been implemented effectively in a wide range of studies to detect and quantify oxPTMs. One of the 
first was ICAT (isotope coded affinity tags), and its cleavable version cICAT, which are commercially 
available cysteine-specific tags based on an iodoacetamide (IAM)-based thiol-reactive group, and also 
carry an affinity tag for the enrichment of tagged peptides. ICAT has been effectively used to quantify 
evidence of cysteine oxidation in complex protein mixtures [92,93]. It has the advantage that enrichment 
can improve the depth of the analysis, but a significant disadvantage is that the presence of the ICAT 
tag can affect the quality of MS/MS data [94]. Other reagents have been recently developed for cysteine 
oxidation analysis. Isotope-labeled N-ethylmaleimide (NEM) has been used in a targeted MS approach 
to monitor the redox status of reversibly oxidized cysteines and the detection and analysis of cysteine 
disulfide bonds [95], and IAM based strategies are now being further developed for the detection and 
quantification of protein S-nitrosothiols (SNOs, recently reviewed in [92]). The recently commercially 
available iodoacetyl tandem mass tag (iodoTMT) six-plex reagent has been used for MS identification 
and quantification of SNOs [27,96], as well as other cysteine oxidations such as glutathionylation, 
nitrosoglutathione, and disulfides [96]. The TMT isobaric tags have been adapted recently for the comparison 
of the relative abundance or cysteine site occupancy by SNOs and sulfenic acids [97], and exploited 
for the detection of SNOs in LPS-stimulated microglial cells [27]. 
The use of iTRAQ, which labels primary amino groups and was developed for general quantification 
studies, has been extended for analysis of oxPTMs [19]. In combination with NEM-based thiol-blockade, 
iTRAQ has been used to identify the redox-sensitive reversibly-oxidized cysteines in proteins and  
to quantitatively assess the oxidation states of individual cysteine residues [98]. iTRAQ has recently 
been modified to detect other oxPTMs including protein carbonylation [99] and to selectively label  
and quantify 3-nitrotyrosine, both alone and in combination with precursor isotopic labeling [100]. 
Promising results in the detection of other oxPTMs have also been generated using specific enzymatic 
reactions to place the isotope tag at specific amino acid groups. For example, enzyme-catalysed  
O18-based labeling has been successfully used for accurate quantification of oxidized methionine [101]. 
An extension of label-dependent methods is absolute rather than relative quantification, which can 
be particularly valuable for clinical biomarker analysis. The most commonly used method is AQUA [82], 
where a stable isotope-labeled version of the peptide of interest is synthesized and used as an internal 
standard, but this has not yet been applied to oxPTMs. iTRAQ-labeled internal standards have also 
been recently used in combination with targeted MS approaches to quantify evidence of proteolytic 
post translational modifications such as proteolytic cleavage [102] or phosphorylation, but again this 
method has yet to be applied in oxPTM analysis. 
6. Applications in Vivo and in Disease 
OxPTMs can be classified either as reversible modifications, most commonly the lower oxo-forms 
of cysteine and methionine, or irreversible modifications, including cysteine sulfonic acid, methionine 
sulfone, and most oxidation products of other residues. The reversible oxPTMs have generated  
much interest, as evidence is emerging for their role in redox signaling [2]. An increasing number of 
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proteins have been found to be regulated by reversible oxidation of cysteine to sulfenate and disulfide 
forms [103,104], and this has been shown to contribute to physiological control of signaling pathways 
governing cell fate, such as apoptosis, proliferation or inflammatory processes [105]. Some of the best 
known examples include protein tyrosine phosphatases such as PTP1B, apoptosis signal-regulating kinase 
(ASK-1), caspases and peroxiredoxin [106,107]. Other more recently discovered redox-regulated proteins 
include the nuclear signalling protein HMGB1 [108] and Hsp33 [109]. These enzymes contain thiolates 
that are particularly susceptible to oxidation by hydrogen peroxide, which can be generated for example 
by NADPH oxidases following activation of growth factor or other receptors. The role of SNOs  
in enzyme regulation and signalling is also gaining recognition [110], as in studies on mitochondrial 
complex I [111]. Interestingly, there is growing support for the concept that tyrosine nitration has  
a role to play in protein redox signaling [112,113]. While often these are normal, physiological 
processes, there is also evidence that they can be dysregulated in disease or aging, and there have been 
some excellent reviews on this topic recently [103,114], including the application of mass spectrometry 
to support these studies [113,115]. Consequently, the following sections focus instead on examples of 
stable and irreversible modifications to proteins in specific diseases and their potential as biomarkers. 
6.1. Considerations for Clinical Sample Type in oxPTM Analysis 
Despite advances in technology, the determination of oxPTMs in biological and clinical samples 
remains challenging owing to sample complexity, low abundance of the modifications, and potential 
for adventitious oxidation [116]. The low abundance of modifications often encountered in vivo  
means that many studies are initiated by in vitro analysis of highly modified proteins. These often bear 
little relationship to the low levels of oxidative modification encountered in clinical samples  
(e.g., nitration [117]), which means they are relatively poor models for physiological protein 
modification. This is compounded by the poor quantification of some methods, for example in 
carbonyl and glycation analysis [116,118,119]. 
The type and abundance of oxPTMs is dependent on the sample type. The main sources of clinical 
samples for proteomics are body fluids and tissue extracts. Urine and blood are by far the most widely 
studied fluids, owing to the relative ease of their acquisition. Although urine can be obtained non-invasively 
in large volumes and is known to contain a more than 1500 different proteins [120], their concentration 
is too low for routine detection of oxPTMs. Consequently, there have been more studies of free 
oxidized amino acids as markers of protein oxidation. Additionally, collection urine is more susceptible  
to adventitious oxidation during the excretory process. Another non-invasive biological material is 
exhaled breath condensate, which contains a variety of proteins and has potential for early diagnosis of 
lung cancer [121]. In asthma patients, exhaled breath condensate has been found by targeted mass 
spectrometry-based methods to contain free 3-nitrotyrosine [122,123]. Plasma is a better source of 
concentrated proteins (more than 490 proteins have been resolved [124]), and abundant plasma 
proteins such as albumin [125] and fibrinogen [126] are often investigated. Protein analysis can be 
achieved using very small volumes of blood, for example from pinpricks, especially if combined  
with novel approaches such as paper-spray mass spectrometry [127], although this has not as yet been 
applied to oxPTMs. 
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A limitation of plasma is that it reports on the systemic status rather than being disease or organ-specific; 
consequently, it can be desirable to study protein oxidation in other body fluids. For example, cerebrospinal 
fluids have been used to detect products of protein oxidation in Alzheimer’s disease patients [128,129], 
and synovial fluids have been used for the detection of free and protein-bound 3 nitrotyrosine in 
osteoarthritis [130]. Protein oxidation has also been detected in saliva, seminal fluid, and amniotic 
fluid [131–133]. Ultimately, information about protein damage in organs requires the use of tissue 
biopsies to assess the local level of oxidation. Mass spectrometry-based procedures have been used on 
tissue biopsies of tumours [134] and virus-infected tissues [135], and oxidized proteins have been 
reported in surgical biopsies of diseased human tissues such as heart [136] and brain [137] tissue. Even 
with the small sample amounts obtained by needle biopsies, modern approaches and high-resolution 
instruments can profile proteins [138]. MALDI imaging has recently been used for proteomic analysis 
of needle-core biopsied human pancreatic tumour tissue spotted on microarrays, and evidence of 
protein oxidation was reported [139]. 
6.2. MS Analysis of Protein Oxidation in Disease 
A major driver for analysing protein oxidation in biological or human samples is to determine their 
importance in disease [140]. This has two potential benefits: an improved understanding of their role 
or mechanism in the pathological condition, and the identification of improved biomarkers for 
diagnosis. Especially for development of clinical biomarkers, much research has been done on the 
analysis of oxidatively modified amino acids, such free nitrotyrosine or chlorotyrosine, oxidized tryptophan 
products, advanced glycation endproducts (AGEs), lipoxidation adducts, and thiol-containing compounds, 
and many well-established targeted MS methods are available [141–149]. Although these methods are 
very useful for gaining an overview of global oxidative damage, they do not yield information on  
the target proteins that have been modified or localize the modification on the protein. The desire for 
greater mechanistic insight has led to the development of the MS methods described in the previous 
sections, and in recent years the application of both label-free and label-dependent mass spectrometry 
methods to clinical analysis has grown exponentially. 
This section will summarize important findings and provide an update on the analysis of oxidized 
proteins in disease. In some studies, elevated levels of oxidized proteins and oxPTMs in disease were 
observed, suggesting their potential as biomarkers, and these findings are summarized in Table 2. 
Although protein identification data for the protein-bound oxPTM(s) detected is provided in all  
these articles, it is important to note that not all of them report site-specific information about the 
modifications, and this limits the confidence of the oxPTM analysis. The oxPTMs that have most often 
been associated with human disease onset are protein carbonyls, 3-nitrotyrosine, 3-chlorotyrosine, 
dityrosine, cysteic acid, cysteine disulfide bonds, cysteine S-glutathionylation, cysteine S-nitrosylation, 
methionine sulfoxide and methionine sulfone. 
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Table 2. Summary of recent studies where increased levels of oxPTMs in disease have been detected using MS techniques.  
Modification 
Type 
Disease  Method Sample Type  Protein Type 
Oxidation Sites 
Identified? 
Reference 
Carbonylation Alzheimer’s disease DNPH, MALDI-TOF/MS Blood (human) 
Fibrinogen -chain precursor 
protein, -1-Antitrypsin precursor 
no 
Choi et al., 2002 
[150] 
Carbonylation Aging 
Avidin affinity,  
LC-MS/MS 
Brain tissue (mouse) Brain proteins yes 
Soreghan et al., 
2003 [151] 
Carbonylation Aging FTCl-labeling; 2DE-MS Liver tissue (mouse) Cytosolic liver proteins no 
Chaudhuri et al., 
2006 [152] 
Carbonylation Aging ITRAQ/LC-MS/MS Skeletal muscle (rat) Mitochondrial muscle proteins no 
Feng et al., 2008 
[153] 
Carbonylation 
Mild Cognitive 
impairment and Early 
Alzheimer’s disease 
DNPH, MALDI-TOF/MS 
inferior parietal 
lobule (human) 
CA II, Syntaxin binding protein I, 
Hsp70, MAPK kinase I, FBA-C, 
PM-1, GFAP 
no 
Sultana et al., 2010 
[154] 
Carbonylation Aging ARP-labeling, MS/MS Heart (rat) Cardiac mitochondrial proteins yes 
Chavez et al., 2011 
[155] 
Carbonylation Diabetes ITRAQ/LS-MS/MS(SRM) Plasma (rat) Plasma proteins yes 
Madian et al., 2011 
[156] 
Carbonylation 
Obesity-induced diabetes 
mellitus 
ARP-labeling RPC-MS/MS Plasma (human) Plasma proteins yes 
Bollineni et al., 
2014 [157] 
Carbonylation Breast cancer iTRAQ Plasma (human) Plasma proteins yes 
 Madian & 
Regnier, 2010 [29] 
Carbonylation Ischemia/reperfusion 
2D-PAGE-MALDI-
TOF/TOF/MS/MS, 
Hippocampus 
(monkey) 
Hsp70-1, DRP2 isoform 2,  
GFAP, -actin  
yes 
Oikawa et al., 2009 
[158] 
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Table 2. Cont. 
Modification 
Type 
Disease  Method Sample Type  Protein Type 
Oxidation Sites 
Identified? 
Reference 
Carbonylation, 
cysteic acid, 
MetO, MetO2 
Alzheimer’s disease, 
Parkinson’s disease 
2D-PAGE, MALDI-TOF/MS 
MALDI-TOF/TOF/MS/MS, 
HPLC-ESI/MS/MS  
MALDI-MS/MS 
Brain (human) DJ-1 yes 
Choi et al., 2006 
[137] 
3-NO2Y Cancer 
NTAC-based MALDI–LTQ 
MS/MS 
Non-functional 
pituitary adenoma 
tissue (human) 
NTAC-enriched proteins  yes 
Zhan & Desiderio, 
2006 [120] 
3-NO2Y, 3-Cl-Y Influenza LC-MS/MS Serum (mouse) Serum proteins yes 
Kumar et al., 2014 
[159] 
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Protein carbonyl formation is one of the most studied and well-established markers of oxidative 
stress-related human diseases [160]; usually chemical tagging for enrichment is used, as described in 
Section 2.2. Many clinical and disease-related investigations used untargeted MS or MS/MS methods 
to analyse gel spots from 2D-electrophoresis of DNPH-derivatised proteins techniques; this identifies 
the proteins present in gel spots that have been identified as carbonyl-containing by immuno-staining, 
but it is important to remember that unless the modification has been localized on the proteins of 
interest by MS/MS analysis and ideally by de novo sequencing, the identification of carbonyl-modified 
proteins is tentative. Using such approaches, evidence of increased levels of protein carbonyls have 
been detected in tissues from patients Alzheimer’s disease [132,150,154,161], and in aged rat skeletal 
muscle with quantification by iTRAQ based-methods [153]. 
In other studies, the DNPH label or other chemical tag has been further utilized for targeted MS/MS 
analysis. For example, protein carbonylation sites have been determined and validated in rat cardiac 
mitochondrial proteins using aldehyde/keto reactive probes (ARP) and avidin-based affinity enrichment 
coupled with LC-MS/MS [155]. The methodology was subsequently applied to study adducts of reactive 
lipid aldehydes in hearts of young and old rats, and interestingly the level of hydroxyhexanal-modified 
proteins was higher in mitochondria from young animals, in line with the concept that these mitochondria 
contain higher levels of omega-3 (n3) fatty acids. On the other hand, the location and increased levels 
of carbonyls have been reported in proteins of aged mouse brain [151]. Ischaemia/reperfusion is known 
to cause oxidative stress, and increased carbonyl modification of Hsp70 and several neuron-specific 
proteins have been observed in monkey hippocampus [158]. Bollineni et al. used the carbonyl-reactive 
probe O-(biotinylcarbazoylmethyl)hydroxylamine followed by avidin affinity chromatography to 
demonstrate differences in the profiles of carbonyl-containing proteins in plasma of obese subjects and 
patients with type 2 diabetes [157]. The carbonyl status of 35 different proteins has also been mapped 
in diabetic rat plasma, and was found to increase significantly in 11 of them [156]. This group also 
investigated carbonyl-containing proteins in plasma of breast cancer patients and found that they were 
strongly associated with the breast cancer type-1 susceptibility protein Brca1 [162]. These studies built 
on a high through-put methodology incorporating carbonyl-labeling and iTRAQ for quantifying 
protein carbonyl analysis in human plasma [29]. 
The redox processes of cysteine, both reversible and irreversible, are also of emerging clinical 
relevance [163,164]. Reversible cysteine oxidation has been found using proteomics approaches in  
the skeletal muscle of aged rats [165]. Untargeted MS/MS approaches have been used to provide 
evidence of irreversible cysteine oxidation in different proteins in brain tissue of patients with 
Alzheimer’s or Parkinson’s diseases [137,161,166]. Cysteine SNOs have been also linked to aging  
and Alzheimer’s disease, according to a proteomics study on human brain samples [167]. Interestingly, 
cysteine SNO formation has been reported in mouse models of ischaemia/reperfusion injury using 
SNO-RAC (S-nitrosothiols resin affinity capture) in combination with label-free based quantification [168]. 
Ischemia/reperfusion was also found to cause reversible oxidation of cysteine in heart tissue of mice 
using Redox-ICAT for quantification by MS/MS [169]. A similar approach has been used to study 
redox switches in liver mitochondrial protein samples during cadmium toxicity in rats [170]. 
Methionine oxidation has been much less studied than cysteine oxidation, but evidence is emerging 
for links to a number of human pathologies, including Alzheimer’s [171] and Parkinson’s diseases [172]. 
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Protein-bound methionine sulfoxide (MetO) was found to be elevated in the plasma of diabetic patients [173] 
as well as in the brain tissues of patients affected by Alzheimer’s and Parkinson’s disease. 
Oxidatively modified tyrosines have also been proposed as consistent biomarker of several inflammatory 
and chronic human pathologies [174]. One of the most studied markers of peroxynitrite-mediated 
damage in MS-based studies is 3-nitrotyrosine. As with protein carbonyl formation, many studies have 
utilized anti-nitrotyrosine antibodies for immunoblotting of 2D gels before analysis of gel spots by 
MALDI peptide fingerprinting or untargeted MS/MS methods, and the same limitations apply. In this 
way, elevated levels of protein-bound 3-nitrotyrosine have been detected in proteins from brain tissue 
of Alzheimer’s disease patients [175] and in serum and colon during inflammatory bowel disease [176]. 
Using more rigorous MS approaches, sites of nitrotyrosine formation were identified on high density 
lipoprotein (HDL) and found to be increased during atherosclerosis [177]. Site-specific signatures of 
nitrotyrosine and chlorotyrosine in HDL by neutrophil extracellular trap enzymes have been observed 
in systemic lupus erythematosus (SLE) [178]. In human pituitary non-functional adenoma, nine nitro-proteins 
were identified using a nitrotyrosine affinity column (NTAC); the nitration sites were localized to 
functional domains of the proteins and it was suggested that might contribute to pathogenesis [120]. 
Interestingly, using MS-based strategies elevated levels of protein-bound 3-chlorotyrosine have been 
recently detected in mouse models of influenza [159], as well as in the clinical samples of inflammatory 
bowel disease [176], atherosclerosis [179], SLE [178] and post-myocardial infarction [180], providing 
evidence for the formation of chlorinating species in these inflammatory conditions. 
7. Conclusions and Perspectives 
Oxidative modifications of proteins and the regulation of signalling by oxPTMs are highly topical 
areas of increasingly recognized importance in biomedical science, and the increased levels of several 
oxPTMs in inflammatory diseases offer potential as biomarkers for the development of new 
diagnostics. It is clear that MS-based strategies have greatly underpinned the increase in knowledge  
in this area, and are confidently expected to continue to do so. The chemical enrichment and labelling 
approaches, together with the advanced MS/MS routines described, provide very powerful though 
time-consuming tools for investigating the relationships between specific oxidative modifications of 
proteins and mechanisms of disease pathology. There are many advances that are also helping to provide 
new information. MS imaging promises to be able to provide MS-based histology for mapping oxidative 
modifications across tissues, and although it has been used for mapping oxidised lipids [181], it has not 
yet been used to any significant degree for proteins. The availability, albeit at significant cost, of stable 
isotope-labelled animals (e.g., stable isotope labelling in mammals; SILAM) [182,183] may also 
provide a powerful tool for studying systemic or tissue specific oxidative stress and signalling. The use 
of genetic knockouts is a well-established method for unlocking cellular biochemical mechanisms and 
their roles in disease, and with the introduction of new technologies such as CRISPRi [184], it is set to 
become one of the key technologies for studies on pathology and for both mechanistic studies and 
validation. This has not yet been as widely exploited in the redox field as in others, or for studying 
redox biology in mammals as much as in plants, but promising results have been obtained from a range 
of studies (e.g., [185–187]). Kinetic and systems modelling has become well established in systems 
biology, and this is also now being applied to redox studies using MS and other data to build dynamic 
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and predictive models that can help to understand the underlying biological processes complex regulatory 
dynamics of steady-state levels of protein oxidation [188]. 
However, there are still many challenges. It is essential to understand that analysis of oxPTMs 
involves non-standard proteomics methodology, and an important message of this review is that there 
are many potential pitfalls in the analysis of MS/MS data, which can lead to erroneous identifications 
of oxPTMs and conclusions. Consequently, it is essential to understand the requirements and limitations of 
the techniques used, and select appropriate approaches to address the research question. Although novel 
methods continue to be developed, their translation to early diagnosis tools for clinical settings 
continues to be difficult, owing to factors such as lack of well-established validation protocols for 
oxPTMs, the wide variety of methodologies, and complex data analysis [189]. In the meantime, the 
scientific community will continue to benefit from the advances in methodology and applications 
described in this article. 
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